Cells (Jun 2022)

Cytoplasmic LMO2-LDB1 Complex Activates STAT3 Signaling through Interaction with gp130-JAK in Glioma Stem Cells

  • Cheol Gyu Park,
  • Sang-Hun Choi,
  • Seon Yong Lee,
  • Kiyoung Eun,
  • Min Gi Park,
  • Junseok Jang,
  • Hyeon Ju Jeong,
  • Seong Jin Kim,
  • Sohee Jeong,
  • Kanghun Lee,
  • Hyunggee Kim

DOI
https://doi.org/10.3390/cells11132031
Journal volume & issue
Vol. 11, no. 13
p. 2031

Abstract

Read online

The oncogenic role of nuclear LIM domain only 2 (LMO2) as a transcriptional regulator is well established, but its function in the cytoplasm is largely unknown. Here, we identified LMO2 as a cytoplasmic activator for signal transducer and activator of transcription 3 (STAT3) signaling in glioma stem cells (GSCs) through biochemical and bioinformatics analyses. LMO2 increases STAT3 phosphorylation by interacting with glycoprotein 130 (gp130) and Janus kinases (JAKs). LMO2-driven activation of STAT3 signaling requires the LDB1 protein and leads to increased expression of an inhibitor of differentiation 1 (ID1), a master regulator of cancer stemness. Our findings indicate that the cytoplasmic LMO2-LDB1 complex plays a crucial role in the activation of the GSC signaling cascade via interaction with gp130 and JAK1/2. Thus, LMO2-LDB1 is a bona fide oncogenic protein complex that activates either the JAK-STAT signaling cascade in the cytoplasm or direct transcriptional regulation in the nucleus.

Keywords